Patients in the phase 3 LIBREXIA ACS trial showed no reduction in cardiovascular events after acute coronary syndrome.
Despite a major reduction in transthyretin amyloid deposits, eplontersen, a drug that reduces TTR production, did not reduce events associated with TTR amyloidosis in a phase 3 trial.
Statin use for primary cardiovascular prevention in adults aged 70 years or older is supported by data from STAREE, although treatment did not prolong disability-free survival.
Hallmark signs of pediatric pneumonia, including crackles and decreased breath sounds, shows low reliability between ...
A novel ultrasound-derived score combined with liver stiffness measurement can identify both MASH and fibrosis, potentially ...
Lumbar CT attenuation measurements outperform MRI-derived vertebral bone quality scores for diagnosing osteopenia and ...
Visible hyperpigmentation may mask persistent erythema and should not be assumed to indicate resolved inflammation,’ ...
A prospective study shows that lower levels of physical exercise are consistently associated with a higher risk for common ...
Anticoagulation reduced adverse clinical events in patients with atrial fibrillation at intermediate stroke risk, without an ...
The ERC’s 2025 pediatric resuscitation update simplifies airway management, drug dosing, and post-ROSC care to help teams act ...
In a phase 3 trial, adding a combo of two traditional Chinese meds to metformin reduced A1c and improved lipid measure in ...
The assay’s significant limitation is its inability to assess drug resistance for integrase inhibitors, including ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results